News
News
Current news articles are found here.
Production of drugs in SA instead of outsourcing to countries such as India would dent high unemployment.
Public-private partnerships in the pharmaceutical sector are vital for accelerating job creation and infrastructure development in SA, says malaria researcher Kelly Chibale.
An exciting new antimalarial drug candidate is active across the entire parasite life cycle and holds great promise as a single-dose cure.
A new paper published today in the prestigious journal Science Translational Medicine describes the discovery and biological profiling of an exciting new antimalarial clinical drug candidate. MMV390048 is effective against resistant strains of the malaria parasite and across the entire parasite life cycle, and it has the potential to cure and protect in a single dose.
A new paper published today in the prestigious journal Science Translational Medicine describes the discovery and biological profiling of an exciting new anti-malarial clinical drug candidate, MMV390048, effective against resistant strains of the malaria parasite, and across the entire parasite lifecycle, with the potential to cure and protect in a single dose. The research was conducted by the University of Cape Town (UCT)'s Drug Discovery and Development Centre, H3D, and Medicines for Malaria Venture (MMV), in collaboration with a team of international researchers.
Click here to watch the Beautiful News video
The scientist poised to save millions from the devastation of malaria
Africa has been at the mercy of Malaria for thousands of years. Killing half a million people on the continent each year, the disease is yet to meet its equal. But this could soon change. A team of young scientists at UCT has uncovered a compound that has the potential to attack Malaria at all three stages of its cycle through the human body, with a force beyond anything in modern medicine.
Professor Dame Sally Davies, the Chief Medical Officer for England and UK government adviser, has appointed an expert advisory board to support the Global Antimicrobial Resistance Innovation Fund (GAMRIF).
The 12 member board will advise how the UK can best spend an additional £50 million over the next 5 years to work with global partners to fund innovative initiatives to tackle drug resistant infections, which includes resistance to antibiotics.
The UK government has appointed an expert advisory board to advise how it can best spend an additional 50 million British pounds over the next five years to fund innovative initiatives to tackle drug resistant infections, which include resistance to antibiotics.
Professor Kelly Chibale, founder and director of the University of Cape Town’s Drug Discovery and Development Centre (H3D) and founding director of the South African Medical Research Council/UCT drug discovery and development research unit, has been selected as a member of the advisory board.
Today 193 countries will sign a landmark declaration agreeing to combat the biggest risk to modern medicine – antimicrobial resistance – at the United Nations General Assembly in New York.
The University of Cape Town (UCT)’s Drug Discovery and Development Centre, H3D, has identified a new potent anti-malarial development candidate with potential for both treatment and prevention of malaria
Maison de la Paix, Chemin Eugène-Rigot 2, 1202 Geneva
Please join us at this year’s World Health Assembly for a conversation with product developers on developing and scaling essential
health technologies. This moderated panel discussion will explore the current challenges of incentivising the development of innovative technologies that address the burden of disease globally, specifically poverty related and neglected diseases, while ensuring they are accessible to those most in need. Representatives from industry, academia, and nonprofit product development partnerships will debate the most significant barriers to access, and share successes, challenges, and lessons learned from a product developer’s perspective.
The University of Cape Town’s Drug Discovery and Development Centre, H3D, has entered into a strategic partnership with Janssen Pharmaceutica N.V., one of the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen), aimed at jointly identifying and addressing the unique issues of advanced drug development in Africa.
The Universities of Dundee (Scotland) and Cape Town (South Africa) have linked up with the industrial expertise of the pharmaceuticals division of Germany’s Bayer (BAYN: DE), in an effort to develop critically needed new treatments for tuberculosis (TB). The collaboration combines some of the world’s best knowledge on TB biology, drug discovery and medicinal chemistry, with access to an industrial library of chemical compounds.
The recent launch of H3D’s state-of-the-art, R22 million medicinal chemistry laboratory marks a new chapter in the university’s drug discovery programme.
Pages
- 1
- 2